Merk D - Search Results

1

Design and Structural Optimization of Dual FXR/PPARδ Activators.

Schierle S, Neumann S, Heitel P, Willems S, Kaiser A, Pollinger J, Merk D. Schierle S, et al. Among authors: merk d. J Med Chem. 2020 Aug 13;63(15):8369-8379. doi: 10.1021/acs.jmedchem.0c00618. Epub 2020 Jul 20. J Med Chem. 2020. PMID: 32687365

2

Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?

Merk D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 Apr;4(5):587-8. doi: 10.4155/fmc.12.8. Future Med Chem. 2012. PMID: 22458677 No abstract available.

3

Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.

Merk D, Steinhilber D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 May;4(8):1015-36. doi: 10.4155/fmc.12.47. Future Med Chem. 2012. PMID: 22650242 Review.

4

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).

Lamers C, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Expert Opin Ther Pat. 2012 Jul;22(7):803-41. doi: 10.1517/13543776.2012.699042. Epub 2012 Jun 15. Expert Opin Ther Pat. 2012. PMID: 22697317 Review.

5

Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.

Merk D, Steinhilber D, Schubert-Zsilavecz M. Merk D, et al. Expert Opin Drug Discov. 2014 Jan;9(1):27-37. doi: 10.1517/17460441.2014.860129. Epub 2013 Nov 21. Expert Opin Drug Discov. 2014. PMID: 24261510 Review.

6

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).

Merk D, Gabler M, Gomez RC, Flesch D, Hanke T, Kaiser A, Lamers C, Werz O, Schneider G, Schubert-Zsilavecz M. Merk D, et al. Bioorg Med Chem. 2014 Apr 15;22(8):2447-60. doi: 10.1016/j.bmc.2014.02.053. Epub 2014 Mar 15. Bioorg Med Chem. 2014. PMID: 24685112

7

Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.

Merk D, Lamers C, Ahmad K, Carrasco Gomez R, Schneider G, Steinhilber D, Schubert-Zsilavecz M. Merk D, et al. J Med Chem. 2014 Oct 9;57(19):8035-55. doi: 10.1021/jm500937v. Epub 2014 Sep 25. J Med Chem. 2014. PMID: 25255039

8

Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.

Lamers C, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Curr Top Med Chem. 2014;14(19):2188-205. doi: 10.2174/1568026614666141112103516. Curr Top Med Chem. 2014. PMID: 25388533 Review.

9

Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.

Merk D, Lamers C, Weber J, Flesch D, Gabler M, Proschak E, Schubert-Zsilavecz M. Merk D, et al. Bioorg Med Chem. 2015 Feb 1;23(3):499-514. doi: 10.1016/j.bmc.2014.12.013. Epub 2014 Dec 19. Bioorg Med Chem. 2015. PMID: 25583100

10

Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

Flesch D, Gabler M, Lill A, Gomez RC, Steri R, Schneider G, Stark H, Schubert-Zsilavecz M, Merk D. Flesch D, et al. Among authors: merk d. Bioorg Med Chem. 2015 Jul 1;23(13):3490-8. doi: 10.1016/j.bmc.2015.04.035. Epub 2015 Apr 18. Bioorg Med Chem. 2015. PMID: 25934227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters